William Love
Founder presso DESTINY PHARMA PLC
Patrimonio netto: 2 M $ in data 31/03/2024
Profilo
William Guy Love is the founder of Destiny Pharma Plc, a company founded in 1996.
He currently holds the title of Chief Scientific Officer & Executive Director at Destiny Pharma Plc.
In addition to his founding position, Dr. Love also held a former job as a Founding Member at Beam Alliance.
Partecipazioni note in società pubbliche
Società | Data | Numero di azioni | Valorizzazione | Data di valutazione |
---|---|---|---|---|
DESTINY PHARMA PLC
6.83% | 18/10/2023 | 6 509 500 ( 6.83% ) | 2 M $ | 31/03/2024 |
Posizioni attive di William Love
Società | Posizione | Inizio |
---|---|---|
DESTINY PHARMA PLC | Founder | 04/03/1996 |
Precedenti posizioni note di William Love
Società | Posizione | Fine |
---|---|---|
Beam Alliance
Beam Alliance Pharmaceuticals: MajorHealth Technology Beam Alliance is a French company that collaborates with the existing community of stakeholders to foster tangible policies and incentives for the discovery and development of novel antibacterial therapies and diagnostics. The private company is based in Paris, France. The company is aware of the problem arising from the lack of differentiation between different antimicrobials and has set up a dedicated scientific team, namely the Beam Task Force - E (BTF-E), to tackle the issue and propose solutions for better evaluating antimicrobial efficacy within a regulatory context. The company was founded by Florence Séjourné. | Corporate Officer/Principal | - |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
Società quotate in Borsa | 1 |
---|---|
DESTINY PHARMA PLC | Health Technology |
Aziende private | 1 |
---|---|
Beam Alliance
Beam Alliance Pharmaceuticals: MajorHealth Technology Beam Alliance is a French company that collaborates with the existing community of stakeholders to foster tangible policies and incentives for the discovery and development of novel antibacterial therapies and diagnostics. The private company is based in Paris, France. The company is aware of the problem arising from the lack of differentiation between different antimicrobials and has set up a dedicated scientific team, namely the Beam Task Force - E (BTF-E), to tackle the issue and propose solutions for better evaluating antimicrobial efficacy within a regulatory context. The company was founded by Florence Séjourné. | Health Technology |
- Borsa valori
- Insiders
- William Love